# EDGAR Filing Document

**Accession Number:** 0001738021
**File Stem:** 0001193125-23-010952
**Filing Date:** 2023-1
**Character Count:** 2455
**Document Hash:** a887884f633dfad0de9e02b56062c306
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-010952.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001193125-23-010952

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Compass Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001738021
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135
- **BUSINESS PHONE:** 617-500-8099

**MAIL ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Olivia Ventures, Inc.
- **DATE OF NAME CHANGE:** 20180419

**COMPASS THERAPEUTICS, INC.** 

**80 Guest Street** 

**Suite 601** 

**Boston, Massachusetts 02135** 

January 19, 2023

**<u>Via EDGAR Transmission</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: <u>Compass Therapeutics, Inc.: Registration Statement on Form</u> <u>S-3 filed December</u> <u>2, 2022 (File No.</u> <u>333-268652)</u>

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Compass Therapeutics, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to January 20, 2023, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.

---

| |
|:---|
| Sincerely, |
| Compass Therapeutics, Inc.<br>|
| /s/ Vered Bisker-Leib |
| Vered Bisker-Leib |
| President and Chief Operating Officer |

---

cc: Vered Bisker-Leib, *Compass Therapeutics, Inc.*

Jonathan Anderman, *Compass Therapeutics, Inc.*

Richard Hoffman, Esq., *Goodwin Procter LLP*

James Xu, Esq., *Goodwin Procter LLP*